A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
The purpose of this study is to find a safe and effective dose of Erbitux and Iressa for subject with non small cell lung cancer.
Non-Small-Cell Lung Carcinoma
DRUG: Cetuximab + Gefitinib
Safe and effective dose of combination of Erbitux and Iressa therapy.
Response will be measured by radiographic measurement of disease every 4 weeks.
The purpose of this study is to find a safe and effective dose of Erbitux and Iressa for subject with non small cell lung cancer.